- Home
- PHGE vs IMCC Comparison
PHGE vs IMCC Comparison
Compare PHGE & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- IMCC
- Stock Information
- Founded
- PHGE 2015
- IMCC 1980
- Country
- PHGE Israel
- IMCC Israel
- Employees
- PHGE N/A
- IMCC N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- PHGE Health Care
- IMCC Health Care
- Exchange
- PHGE Nasdaq
- IMCC Nasdaq
- Market Cap
- PHGE 11.0M
- IMCC 10.0M
- IPO Year
- PHGE N/A
- IMCC N/A
- Fundamental
- Price
- PHGE $0.42
- IMCC $3.55
- Analyst Decision
- PHGE Strong Buy
- IMCC
- Analyst Count
- PHGE 1
- IMCC 0
- Target Price
- PHGE $15.00
- IMCC N/A
- AVG Volume (30 Days)
- PHGE 265.4K
- IMCC 146.8K
- Earning Date
- PHGE 08-13-2025
- IMCC 08-13-2025
- Dividend Yield
- PHGE N/A
- IMCC N/A
- EPS Growth
- PHGE N/A
- IMCC N/A
- EPS
- PHGE N/A
- IMCC N/A
- Revenue
- PHGE N/A
- IMCC $37,894,737.00
- Revenue This Year
- PHGE N/A
- IMCC $47.12
- Revenue Next Year
- PHGE N/A
- IMCC $12.83
- P/E Ratio
- PHGE N/A
- IMCC N/A
- Revenue Growth
- PHGE N/A
- IMCC 12.68
- 52 Week Low
- PHGE $0.34
- IMCC $1.29
- 52 Week High
- PHGE $3.86
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- PHGE 39.46
- IMCC 60.91
- Support Level
- PHGE $0.42
- IMCC $2.37
- Resistance Level
- PHGE $0.47
- IMCC $3.50
- Average True Range (ATR)
- PHGE 0.05
- IMCC 0.38
- MACD
- PHGE 0.00
- IMCC 0.05
- Stochastic Oscillator
- PHGE 47.00
- IMCC 84.73
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.